Abstract
Background: Although the vast majority of patients with chronic myeloid leukemia (CML) respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate, resistance might occur de novo or during treatment. Methods: The authors reviewed the known mechanisms of primary and secondary resistance to imatinib and other TKIs used in the management of CML. Results: Mutations within the kinase domain of BCR-ABLI account for 30% to 40% of cases of imatinib resistance. Other mechanisms include BCR-ABLI amplification, overexpression of the SRC family of kinases, and pharmacokinetic and pharmacodynamic factors. Conclusions: Although not all resistance mechanisms have been identified and understood, several agents based on the known mechanisms have already been designed and developed and are beginning clinical trials.
Original language | English (US) |
---|---|
Pages (from-to) | 122-131 |
Number of pages | 10 |
Journal | Cancer Control |
Volume | 16 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2009 |
ASJC Scopus subject areas
- Hematology
- Oncology